FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044499768> ?p ?o ?g. }

• W2044499768 endingPage "1073" @default.
• W2044499768 startingPage "1067" @default.
• W2044499768 abstract "The aim of this phase II study was to evaluate safety and efficacy of an oxaliplatin/vinorelbine/5-fluorouracil (FON) combination in anthracycline and taxane-pretreated metastatic breast cancer patients. The following treatment was given: on day 1 of a 21-day cycle, oxaliplatin 130 mg/m2 (2-h intravenous infusion); on days 1 and 5, vinorelbine [dose level (DL) 1: 17.5 mg/m2; DL2: 22 mg/m2]; on days 1–5, continuous infusion 5-fluorouracil (DL1: 600 mg/m2/day; DL2: 750 mg/m2/day). Forty-seven patients were treated (DL1: 43; DL2: 4). Median age was 54 years; 68% had liver metastases, 53% were taxane refractory/resistant and 38% were anthracycline refractory/resistant. Patients received a median of six treatment cycles. Of 46 eligible patients, 16 had partial response; the overall response rate was 34.8% (95% confidence interval 21.3–50.3%), 11 had stable disease lasting more than 4 months. Median follow-up was 13.0 months, median time to progression 5.7 months and estimated overall survival 18.8 months. DL2 was too toxic with three patients having grade 3–4 toxicity, including one death. At DL1, 26 patients (60%) experienced grade 3–4 neutropenia (six febrile neutropenia) and eight had grade 3 oxaliplatin-specific peripheral neuropathy after a median of 646.4 mg/m2 oxaliplatin (range 124–1619 mg/m2). Oxaliplatin (130 mg/m2, day 1)/vinorelbine (17.5 mg/m2, days 1,5)/5-fluorouracil (600 mg/m2/day, days 1–5) demonstrate encouraging activity and a manageable safety profile in anthracycline- and taxane-pretreated metastatic breast cancer patients." @default.
• W2044499768 created "2016-06-24" @default.
• W2044499768 creator A5011160865 @default.
• W2044499768 creator A5021409571 @default.
• W2044499768 creator A5026462289 @default.
• W2044499768 creator A5046350905 @default.
• W2044499768 creator A5049369439 @default.
• W2044499768 creator A5050228664 @default.
• W2044499768 creator A5052920067 @default.
• W2044499768 creator A5055631929 @default.
• W2044499768 creator A5069841014 @default.
• W2044499768 creator A5071867163 @default.
• W2044499768 creator A5072502548 @default.
• W2044499768 creator A5089385974 @default.
• W2044499768 date "2006-10-01" @default.
• W2044499768 modified "2023-09-25" @default.
• W2044499768 title "A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer" @default.
• W2044499768 cites W1521419744 @default.
• W2044499768 cites W1755746957 @default.
• W2044499768 cites W1828283074 @default.
• W2044499768 cites W1837926236 @default.
• W2044499768 cites W1918151945 @default.
• W2044499768 cites W1939600168 @default.
• W2044499768 cites W1966574632 @default.
• W2044499768 cites W1984988266 @default.
• W2044499768 cites W2004853608 @default.
• W2044499768 cites W2010397777 @default.
• W2044499768 cites W2019118254 @default.
• W2044499768 cites W2029409133 @default.
• W2044499768 cites W2032553799 @default.
• W2044499768 cites W2035881635 @default.
• W2044499768 cites W2041545692 @default.
• W2044499768 cites W2051812342 @default.
• W2044499768 cites W2059234543 @default.
• W2044499768 cites W2066708465 @default.
• W2044499768 cites W2075213874 @default.
• W2044499768 cites W2080831848 @default.
• W2044499768 cites W2085566855 @default.
• W2044499768 cites W2093347388 @default.
• W2044499768 cites W2104126300 @default.
• W2044499768 cites W2107577958 @default.
• W2044499768 cites W2110722295 @default.
• W2044499768 cites W2114159573 @default.
• W2044499768 cites W2115931762 @default.
• W2044499768 cites W2119541084 @default.
• W2044499768 cites W2122731269 @default.
• W2044499768 cites W2122970222 @default.
• W2044499768 cites W2139248078 @default.
• W2044499768 cites W2142102721 @default.
• W2044499768 cites W2143399650 @default.
• W2044499768 cites W2155765904 @default.
• W2044499768 cites W2170866964 @default.
• W2044499768 cites W2171684168 @default.
• W2044499768 doi "https://doi.org/10.1097/01.cad.0000231475.77159.aa" @default.
• W2044499768 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17001180" @default.
• W2044499768 hasPublicationYear "2006" @default.
• W2044499768 type Work @default.
• W2044499768 sameAs 2044499768 @default.
• W2044499768 citedByCount "14" @default.
• W2044499768 countsByYear W20444997682012 @default.
• W2044499768 countsByYear W20444997682018 @default.
• W2044499768 countsByYear W20444997682022 @default.
• W2044499768 crossrefType "journal-article" @default.
• W2044499768 hasAuthorship W2044499768A5011160865 @default.
• W2044499768 hasAuthorship W2044499768A5021409571 @default.
• W2044499768 hasAuthorship W2044499768A5026462289 @default.
• W2044499768 hasAuthorship W2044499768A5046350905 @default.
• W2044499768 hasAuthorship W2044499768A5049369439 @default.
• W2044499768 hasAuthorship W2044499768A5050228664 @default.
• W2044499768 hasAuthorship W2044499768A5052920067 @default.
• W2044499768 hasAuthorship W2044499768A5055631929 @default.
• W2044499768 hasAuthorship W2044499768A5069841014 @default.
• W2044499768 hasAuthorship W2044499768A5071867163 @default.
• W2044499768 hasAuthorship W2044499768A5072502548 @default.
• W2044499768 hasAuthorship W2044499768A5089385974 @default.
• W2044499768 hasConcept C121608353 @default.
• W2044499768 hasConcept C126322002 @default.
• W2044499768 hasConcept C141071460 @default.
• W2044499768 hasConcept C2775930923 @default.
• W2044499768 hasConcept C2776694085 @default.
• W2044499768 hasConcept C2776802502 @default.
• W2044499768 hasConcept C2777063308 @default.
• W2044499768 hasConcept C2777511904 @default.
• W2044499768 hasConcept C2778239845 @default.
• W2044499768 hasConcept C2778850193 @default.
• W2044499768 hasConcept C2780350996 @default.
• W2044499768 hasConcept C2780456651 @default.
• W2044499768 hasConcept C2780962732 @default.
• W2044499768 hasConcept C31760486 @default.
• W2044499768 hasConcept C526805850 @default.
• W2044499768 hasConcept C530470458 @default.
• W2044499768 hasConcept C71924100 @default.
• W2044499768 hasConcept C90924648 @default.
• W2044499768 hasConceptScore W2044499768C121608353 @default.
• W2044499768 hasConceptScore W2044499768C126322002 @default.
• W2044499768 hasConceptScore W2044499768C141071460 @default.
• W2044499768 hasConceptScore W2044499768C2775930923 @default.
• W2044499768 hasConceptScore W2044499768C2776694085 @default.

• next